A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or i...

por Petrylak, D.P., Vaishampayan, U.N., Patel, K.R., Higano, C.S., Albany, C., Dawson, N.A., Mehlhaff, B.A., Quinn, D.I., Nordquist, L.T., Wagner, V.J., Siegel, J., Trandafir, L., Sartor, O.
Publicado 2021

Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases

por Sartor, O., Heinrich, D., Mariados, N., Méndez Vidal, M. J., Keizman, D., Thellenberg Karlsson, C., Peer, A., Procopio, G., Frank, S. J., Pulkkanen, K., Rosenbaum, E., Severi, S., Trigo Perez, J. M., Wagner, V., Li, R., Nordquist, L. T.
Publicado 2017